{
  "id": "map_1856",
  "title": "CLIMATERIO Y\\NTERAPIA HORMONAL",
  "specialty": "Endocrinología",
  "tag": "⭐ Estudio Pivotal",
  "node_count": 507,
  "root": {
    "text": "CLIMATERIO Y\\NTERAPIA HORMONAL",
    "children": [
      {
        "text": "DEFINICIONES\\NCLAVE:",
        "children": [
          {
            "text": "Climaterio:",
            "children": [
              {
                "text": "→ Período extenso vida mujer",
                "children": []
              },
              {
                "text": "→ Comprende:",
                "children": [
                  {
                    "text": "• Pre-menopausia",
                    "children": []
                  },
                  {
                    "text": "• Post-menopausia + senectud",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ Característica: ↓ gradual función ovárica (5)",
                "children": []
              }
            ]
          },
          {
            "text": "Menopausia:",
            "children": [
              {
                "text": "→ Última menstruación",
                "children": []
              },
              {
                "text": "→ Causa: ↓ actividad folicular ovárica",
                "children": []
              },
              {
                "text": "→ Dx: retrospectivo (12m sin menstruación) (5)",
                "children": []
              }
            ]
          },
          {
            "text": "IOP (Insuficiencia\\NOvárica Primaria):",
            "children": [
              {
                "text": "→ Antes: FOP (Falla Ovárica Prematura)",
                "children": []
              },
              {
                "text": "→ = amenorrea < 40a",
                "children": []
              },
              {
                "text": "→ Prevalencia: 0. 9-1.2%",
                "children": []
              },
              {
                "text": "→ Etiología:",
                "children": [
                  {
                    "text": "• Idiopática (mayoría)",
                    "children": []
                  },
                  {
                    "text": "• 2ª quimio/radioterapia",
                    "children": []
                  },
                  {
                    "text": "• Post-Qx",
                    "children": []
                  },
                  {
                    "text": "• Sd. Turner",
                    "children": []
                  },
                  {
                    "text": "• Autoinmune",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ Manifestación: hipogonadismo hipergonadotrópico (6)",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "EPIDEMIOLOGÍA:",
        "children": [
          {
            "text": "→ Edad normal: 45-55a (7)",
            "children": []
          },
          {
            "text": "→ Menopausia precoz < 40-45a",
            "children": []
          },
          {
            "text": "• ↑ riesgo osteoporosis",
            "children": []
          },
          {
            "text": "• ↑ riesgo cardiovascular",
            "children": []
          },
          {
            "text": "→ Factores\\Nriesgo adelanto:",
            "children": [
              {
                "text": "• Pobreza",
                "children": []
              },
              {
                "text": "• ↓ nivel educativo",
                "children": []
              },
              {
                "text": "• Altitud > 2000m (8)",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "CONSECUENCIAS\\NHIPOESTROGENISMO:",
        "children": [
          {
            "text": "→ Sx vasomotores:",
            "children": [
              {
                "text": "• + frecuentes en climaterio",
                "children": []
              },
              {
                "text": "• Duración: hasta 2a post-menopausia",
                "children": []
              },
              {
                "text": "• Afecta: 66% mujeres",
                "children": []
              },
              {
                "text": "• Intensos: 25% casos",
                "children": []
              },
              {
                "text": "• Persistencia posible: 15a (9)",
                "children": []
              }
            ]
          },
          {
            "text": "Atrofia\\NUrogenital:",
            "children": [
              {
                "text": "→ Progresión: desde transición menopáusica",
                "children": []
              },
              {
                "text": "→ Sx principales:",
                "children": [
                  {
                    "text": "• Sequedad",
                    "children": []
                  },
                  {
                    "text": "• Irritación",
                    "children": []
                  },
                  {
                    "text": "• Prurito vaginal",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ Cambios atróficos:",
                "children": [
                  {
                    "text": "• ↓ volumen labios",
                    "children": []
                  },
                  {
                    "text": "• Estrechamiento introito",
                    "children": []
                  },
                  {
                    "text": "• Inflamación",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ Complicaciones:",
                "children": [
                  {
                    "text": "• Dispareunia",
                    "children": []
                  },
                  {
                    "text": "• Sangrado vaginal",
                    "children": []
                  },
                  {
                    "text": "• ↑ frecuencia miccional",
                    "children": []
                  },
                  {
                    "text": "• Nicturia",
                    "children": []
                  },
                  {
                    "text": "• Urgencia",
                    "children": []
                  },
                  {
                    "text": "• Incontinencia",
                    "children": []
                  },
                  {
                    "text": "• ITU",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ Características: permanentes + progresivos (12)",
                "children": []
              },
              {
                "text": "→ FR principal disfunción sexual 40-59a: sequedad vaginal (13)",
                "children": []
              }
            ]
          },
          {
            "text": "Enfermedad\\NCardiovascular:",
            "children": [
              {
                "text": "→ = causa principal morbimortalidad posmenopáusicas",
                "children": []
              },
              {
                "text": "→ Estudio Framingham:",
                "children": [
                  {
                    "text": "• ↑ frecuencia ECV posmenopáusicas vs premenopáusicas (14)",
                    "children": []
                  },
                  {
                    "text": "→ FR cardiovascular\\Nposmenopausia:",
                    "children": [
                      {
                        "text": "• HTA",
                        "children": []
                      },
                      {
                        "text": "• Dislipidemia",
                        "children": []
                      },
                      {
                        "text": "• Resistencia insulínica",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "text": "Memoria/Estado\\NCognitivo:",
            "children": [
              {
                "text": "→ Ooforectomía:",
                "children": [
                  {
                    "text": "• ↑ deterioro cognitivo",
                    "children": []
                  },
                  {
                    "text": "• ↑ frecuencia demencia",
                    "children": []
                  },
                  {
                    "text": "• > riesgo ↔ < edad Qx (15)",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ Efectos\\Nestrógenos:",
                "children": [
                  {
                    "text": "• ↑ plasticidad sináptica",
                    "children": []
                  },
                  {
                    "text": "• ↑ crecimiento neuronal",
                    "children": []
                  },
                  {
                    "text": "• ↑ neurogénesis hipocampal",
                    "children": []
                  },
                  {
                    "text": "• ↓ apoptosis",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ Neurotransmisores\\Nafectados:",
                "children": [
                  {
                    "text": "• Acetilcolina",
                    "children": []
                  },
                  {
                    "text": "• Serotonina",
                    "children": []
                  },
                  {
                    "text": "• Noradrenalina",
                    "children": []
                  },
                  {
                    "text": "• Dopamina (16)",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "Salud Ósea:",
            "children": [
              {
                "text": "→ Estrógenos:",
                "children": [
                  {
                    "text": "• ↓ actividad osteoclástica",
                    "children": []
                  },
                  {
                    "text": "• ↑ acción osteoblástica",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ Deficiencia → ↑ resorción/↓ formación = pérdida masa ósea",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "DX CLÍNICO/BIOQUÍMICO:",
        "children": [
          {
            "text": "→ Evaluación HC\\Ndebe incluir:",
            "children": [
              {
                "text": "• FR cardiovascular",
                "children": []
              },
              {
                "text": "• FR osteoporosis",
                "children": []
              },
              {
                "text": "• FR Ca mama/ginecológicos",
                "children": []
              },
              {
                "text": "• Hábitos:",
                "children": [
                  {
                    "text": "- Alimentación",
                    "children": []
                  },
                  {
                    "text": "- Ejercicio",
                    "children": []
                  },
                  {
                    "text": "- Tabaquismo",
                    "children": []
                  },
                  {
                    "text": "- Alcohol",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "Examen Físico:",
            "children": [
              {
                "text": "→ Incluir:",
                "children": [
                  {
                    "text": "• PA",
                    "children": []
                  },
                  {
                    "text": "• IMC",
                    "children": []
                  },
                  {
                    "text": "• Ex. mamario",
                    "children": []
                  },
                  {
                    "text": "• Ex. ginecológico + Papanicolaou",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "Tamizaje:",
            "children": [
              {
                "text": "→ Metabolismo\\Nglucídico:",
                "children": [
                  {
                    "text": "• Glicemia ayuno",
                    "children": []
                  },
                  {
                    "text": "• Test tolerancia glucosa",
                    "children": []
                  },
                  {
                    "text": "• HOMA",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ Perfil lipídico",
                "children": []
              },
              {
                "text": "→ TSH",
                "children": []
              },
              {
                "text": "→ Mamografía:",
                "children": [
                  {
                    "text": "• Anual",
                    "children": []
                  },
                  {
                    "text": "• Desde 40a",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ Densitometría ósea:",
                "children": [
                  {
                    "text": "• Si FR osteoporosis",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "text": "TH (TERAPIA HORMONAL):",
        "children": [
          {
            "text": "Indicaciones:",
            "children": [
              {
                "text": "→ Síndrome\\Nclimatérico:",
                "children": [
                  {
                    "text": "• Sx vasomotores significativos",
                    "children": []
                  },
                  {
                    "text": "• Alt. calidad vida",
                    "children": []
                  },
                  {
                    "text": "• Trastornos:",
                    "children": [
                      {
                        "text": "- Sueño",
                        "children": []
                      },
                      {
                        "text": "- Ánimo",
                        "children": []
                      },
                      {
                        "text": "- Función sexual",
                        "children": []
                      },
                      {
                        "text": "- Jaquecas",
                        "children": []
                      },
                      {
                        "text": "- Dolores articulares",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "→ Atrofia\\Nurogenital:",
                "children": [
                  {
                    "text": "• Preferir estrógenos locales",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ IOP + menopausia\\Nadelantada:",
                "children": [
                  {
                    "text": "• Tratar hasta edad promedio menopausia fisiológica",
                    "children": []
                  },
                  {
                    "text": "• Luego: según reaparición sx",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "Contraindicaciones TH:",
            "children": [
              {
                "text": "→ Absolutas:",
                "children": [
                  {
                    "text": "• Ca mama personal",
                    "children": []
                  },
                  {
                    "text": "• Ca\\Nestrógeno-dependientes:",
                    "children": [
                      {
                        "text": "- Endometrial",
                        "children": []
                      },
                      {
                        "text": "- Adenocarcinoma cervical",
                        "children": []
                      },
                      {
                        "text": "- Melanoma",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "• Ca\\Nprogestágeno-dependientes:",
                    "children": [
                      {
                        "text": "- Meningiomas",
                        "children": []
                      },
                      {
                        "text": "- Schwannomas",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "• Sangrado genital no aclarado",
                    "children": []
                  },
                  {
                    "text": "• Hiperplasia endometrial no tratada",
                    "children": []
                  },
                  {
                    "text": "• Trombofilia congénita/adquirida",
                    "children": []
                  },
                  {
                    "text": "• TEP previo",
                    "children": []
                  },
                  {
                    "text": "• Enfermedad coronaria",
                    "children": []
                  },
                  {
                    "text": "• HTA no controlada",
                    "children": []
                  },
                  {
                    "text": "• Hepatopatía aguda",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "PRINCIPIOS\\NGENERALES TH:",
            "children": [
              {
                "text": "Enfoque Global:",
                "children": [
                  {
                    "text": "→ Parte estrategia\\Nintegral:",
                    "children": [
                      {
                        "text": "• Estilo vida",
                        "children": []
                      },
                      {
                        "text": "• Dieta",
                        "children": []
                      },
                      {
                        "text": "• Ejercicio",
                        "children": []
                      },
                      {
                        "text": "• ↓ tabaco",
                        "children": []
                      },
                      {
                        "text": "• Moderación alcohol",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "Personalización:",
                "children": [
                  {
                    "text": "→ Según:",
                    "children": [
                      {
                        "text": "• Síntomas",
                        "children": []
                      },
                      {
                        "text": "• Historia personal/familiar",
                        "children": []
                      },
                      {
                        "text": "• Evidencia científica",
                        "children": []
                      },
                      {
                        "text": "• Preferencias paciente",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "→ Control: médico anual",
                    "children": []
                  },
                  {
                    "text": "→ Dosis: mínima efectiva",
                    "children": []
                  }
                ]
              },
              {
                "text": "Consideraciones\\NÚtero:",
                "children": [
                  {
                    "text": "→ Con útero:",
                    "children": [
                      {
                        "text": "• Estrógenos + progestina",
                        "children": []
                      },
                      {
                        "text": "• Preferir: progesterona micronizada/agonista puro",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "→ Post-histerectomía:",
                    "children": [
                      {
                        "text": "• Solo estrógenos",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "→ Atrofia urogenital + estrógenos vaginales:",
                    "children": [
                      {
                        "text": "• No requiere progestina",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "text": "ESQUEMAS\\NTERAPÉUTICOS:",
            "children": [
              {
                "text": "1. TE\\N(Estrógenos\\NSolos):",
                "children": [
                  {
                    "text": "→ Indicación: mujeres sin útero",
                    "children": []
                  },
                  {
                    "text": "→ Opciones:",
                    "children": [
                      {
                        "text": "• Estradiol oral: 1-2 mg/d",
                        "children": []
                      },
                      {
                        "text": "• Estradiol gel transdérmico: 0.5-1.5 g/día",
                        "children": []
                      },
                      {
                        "text": "• Estradiol parche: 25-50-100 μg/día",
                        "children": []
                      },
                      {
                        "text": "• Estrógenos conjugados equinos oral: 0.3-0.625 mg/día",
                        "children": []
                      },
                      {
                        "text": "• Estrógenos conjugados sintéticos oral: 0.3-0.625 mg/día",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "2. TE+P (Terapia\\NCombinada):",
                "children": [
                  {
                    "text": "→ Indicación: mujeres con útero",
                    "children": []
                  },
                  {
                    "text": "→ Modalidades:",
                    "children": [
                      {
                        "text": "A. Continua:",
                        "children": [
                          {
                            "text": "• E + P diarios",
                            "children": []
                          },
                          {
                            "text": "• Misma dosis",
                            "children": []
                          },
                          {
                            "text": "• Objetivo: endometrio atrófico + evitar sangrado",
                            "children": []
                          }
                        ]
                      },
                      {
                        "text": "B. Secuencial:",
                        "children": [
                          {
                            "text": "• E: dosis descritas",
                            "children": []
                          },
                          {
                            "text": "• P: 10-14d/mes",
                            "children": []
                          },
                          {
                            "text": "• Nota: flujo rojo post-suspensión P (80% casos)",
                            "children": []
                          }
                        ]
                      },
                      {
                        "text": "C. Secuencial\\Ndiscontinua:",
                        "children": [
                          {
                            "text": "• Ciclos E + P",
                            "children": []
                          },
                          {
                            "text": "• Suspensión periódica (7d/mes)",
                            "children": []
                          },
                          {
                            "text": "• En desuso: reaparición síntomas",
                            "children": []
                          }
                        ]
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "text": "ESTRÓGENOS",
            "children": [
              {
                "text": "Dosis\\NEstrógenos:",
                "children": [
                  {
                    "text": "→ Principio: mínima dosis efectiva",
                    "children": []
                  },
                  {
                    "text": "→ Dosis estándar:",
                    "children": [
                      {
                        "text": "• ECE: 0.625 mg",
                        "children": []
                      },
                      {
                        "text": "• Estradiol oral: 1 mg",
                        "children": []
                      },
                      {
                        "text": "• Estradiol\\Ntransdérmico:",
                        "children": [
                          {
                            "text": "- Parche: 50 μg",
                            "children": []
                          },
                          {
                            "text": "- Gel: 1 mg",
                            "children": []
                          }
                        ]
                      }
                    ]
                  },
                  {
                    "text": "DOSIS BAJAS\\NESTRÓGENOS:",
                    "children": [
                      {
                        "text": "Definición:",
                        "children": [
                          {
                            "text": "→ Estradiol: 0.5 mg",
                            "children": []
                          },
                          {
                            "text": "→ ECE/ECS: 0.325 mg",
                            "children": []
                          }
                        ]
                      },
                      {
                        "text": "→ Estradiol\\Ntransdérmico:",
                        "children": [
                          {
                            "text": "• Parche: 25 μg",
                            "children": []
                          },
                          {
                            "text": "• Gel: 0.5 mg",
                            "children": []
                          }
                        ]
                      },
                      {
                        "text": "Beneficios vs. Dosis\\NEstándar ",
                        "children": [
                          {
                            "text": "→ Mantiene masa ósea",
                            "children": []
                          },
                          {
                            "text": "→ ↓ riesgo\\Ncardiovascular:",
                            "children": [
                              {
                                "text": "• ↓ PCR",
                                "children": []
                              },
                              {
                                "text": "• ↓ factores coagulación",
                                "children": []
                              }
                            ]
                          },
                          {
                            "text": "• Nurses Health\\NStudy (20):",
                            "children": [
                              {
                                "text": "- ECE 0.3mg/d",
                                "children": []
                              },
                              {
                                "text": "- ↓ riesgo cardiopatía coronaria: RR 0.54 (IC95%: 0.28-1.06)",
                                "children": []
                              },
                              {
                                "text": "- ↓ riesgo AVC: RR 0.58 (IC95%: 0.37-0.92)",
                                "children": []
                              }
                            ]
                          },
                          {
                            "text": "→ ↓ estímulo\\Nmamario:",
                            "children": [
                              {
                                "text": "• ↓ mastalgia",
                                "children": []
                              },
                              {
                                "text": "• ↓ densidad mamaria",
                                "children": []
                              },
                              {
                                "text": "• Posible ↓ riesgo Ca mama",
                                "children": []
                              }
                            ]
                          },
                          {
                            "text": "→ ↓ estímulo\\Nendometrial:",
                            "children": [
                              {
                                "text": "• Previene hiperplasia",
                                "children": []
                              }
                            ]
                          }
                        ]
                      }
                    ]
                  }
                ]
              },
              {
                "text": "VÍAS\\NADMINISTRACIÓN:",
                "children": [
                  {
                    "text": "Oral vs. No Oral:",
                    "children": [
                      {
                        "text": "→ Eficacia similar:",
                        "children": [
                          {
                            "text": "• Control sx menopáusicos",
                            "children": []
                          },
                          {
                            "text": "• Prevención pérdida ósea",
                            "children": []
                          }
                        ]
                      },
                      {
                        "text": "Efectos Metabólicos\\NTH Oral:",
                        "children": [
                          {
                            "text": "→ Efecto primer\\Npaso hepático:",
                            "children": [
                              {
                                "text": "• Beneficioso:",
                                "children": [
                                  {
                                    "text": "- ↓ LDL",
                                    "children": []
                                  },
                                  {
                                    "text": "- ↑ HDL",
                                    "children": []
                                  }
                                ]
                              },
                              {
                                "text": "• No deseados:",
                                "children": [
                                  {
                                    "text": "- ↑ TG",
                                    "children": []
                                  },
                                  {
                                    "text": "- ↑ factores coagulación",
                                    "children": []
                                  },
                                  {
                                    "text": "- ↑ PCR",
                                    "children": []
                                  }
                                ]
                              }
                            ]
                          }
                        ]
                      },
                      {
                        "text": "TH Transdérmica (21):",
                        "children": [
                          {
                            "text": "→ Preferible en:",
                            "children": [
                              {
                                "text": "• Hipertrigliceridemia",
                                "children": []
                              },
                              {
                                "text": "• Alto riesgo trombótico",
                                "children": []
                              },
                              {
                                "text": "• Alto riesgo cardiovascular",
                                "children": []
                              }
                            ]
                          }
                        ]
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "text": "PROGESTINA:",
            "children": [
              {
                "text": "→ Estrógenos solos:",
                "children": [
                  {
                    "text": "• ↑ estímulo endometrial dosis-dependiente",
                    "children": []
                  },
                  {
                    "text": "• ↑ riesgo hiperplasia/Ca endometrial",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ Mujeres con útero: requieren progestina",
                "children": []
              },
              {
                "text": "Regímenes E+P:",
                "children": [
                  {
                    "text": "→ Combinados continuos:",
                    "children": [
                      {
                        "text": "• ↓ incidencia hiperplasia/Ca endometrial vs. población general",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "→ Dosis bajas/ultra bajas:",
                    "children": [
                      {
                        "text": "• ↓ estímulo endometrial",
                        "children": []
                      },
                      {
                        "text": "• ↓ sangrado",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "→ Ciclo largo\\Nsecuencial:",
                    "children": [
                      {
                        "text": "• E diario + P c/2-4 meses",
                        "children": []
                      },
                      {
                        "text": "• Protección endometrial inadecuada",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "Efectos Específicos\\NProgestinas:",
                "children": [
                  {
                    "text": "→ Progesterona natural:",
                    "children": [
                      {
                        "text": "→ Drospirenona:",
                        "children": [
                          {
                            "text": "• Acción antimineralocorticoide",
                            "children": []
                          },
                          {
                            "text": "• ↓ cifras tensionales",
                            "children": []
                          }
                        ]
                      },
                      {
                        "text": "→ Otras con efecto\\Nantiandrogénico:",
                        "children": [
                          {
                            "text": "• Ciproterona",
                            "children": []
                          },
                          {
                            "text": "• Dienogest",
                            "children": []
                          },
                          {
                            "text": "• Clormadinona",
                            "children": []
                          }
                        ]
                      },
                      {
                        "text": "→ Diferencias\\Nentre progestinas:",
                        "children": [
                          {
                            "text": "• Efectos metabólicos",
                            "children": []
                          },
                          {
                            "text": "• Riesgo Ca mama + E largo plazo (2)",
                            "children": []
                          }
                        ]
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "text": "SX\\NVASOMOTORES:",
        "children": [
          {
            "text": "Generalidades:",
            "children": [
              {
                "text": "→ TH: tto médico más efectivo",
                "children": []
              },
              {
                "text": "→ Alternativas no\\Nhormonales:",
                "children": [
                  {
                    "text": "• Alivian bochornos",
                    "children": []
                  },
                  {
                    "text": "• Tienen EA propios",
                    "children": []
                  },
                  {
                    "text": "• Usar si:",
                    "children": [
                      {
                        "text": "- TH contraindicada",
                        "children": []
                      },
                      {
                        "text": "- Paciente rechaza TH",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "text": "Sx Vasomotores:",
            "children": [
              {
                "text": "→ TE/TE+P = terapia más efectiva",
                "children": []
              },
              {
                "text": "→ Eficacia demostrada :",
                "children": [
                  {
                    "text": "• ECE",
                    "children": []
                  },
                  {
                    "text": "• Estradiol",
                    "children": []
                  },
                  {
                    "text": "• Vía oral/transdérmica",
                    "children": []
                  },
                  {
                    "text": "• ↓ 80-95% frecuencia/intensidad bochornos",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "Alternativas:",
            "children": [
              {
                "text": "→ Tibolona (25):",
                "children": [
                  {
                    "text": "• Eficacia < TH",
                    "children": []
                  },
                  {
                    "text": "• Considerar efectos perfil lipídico",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ No hormonales eficaces\\N> placebo (26,27):",
                "children": [
                  {
                    "text": "• Clonidina",
                    "children": []
                  },
                  {
                    "text": "• Gabapentina",
                    "children": []
                  },
                  {
                    "text": "• ISRS:",
                    "children": [
                      {
                        "text": "- Paroxetina",
                        "children": []
                      },
                      {
                        "text": "- Citalopram",
                        "children": []
                      },
                      {
                        "text": "- Venlafaxina",
                        "children": []
                      },
                      {
                        "text": "- Desvenlafaxina",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "text": "Fitoestrógenos (28):",
            "children": [
              {
                "text": "→ Revisión\\NCochrane 2010:",
                "children": [
                  {
                    "text": "• 30 estudios",
                    "children": []
                  },
                  {
                    "text": "• Mayoría: corta duración + baja calidad",
                    "children": []
                  },
                  {
                    "text": "• Conclusión: no evidencia efectividad",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "text": "SX UROGENITALES:",
        "children": [
          {
            "text": "→ Respuesta favorable a estrógenos",
            "children": []
          },
          {
            "text": "→ Estrógenos\\Nlocales dosis bajas:",
            "children": [
              {
                "text": "• Sin riesgos sistémicos identificados",
                "children": []
              },
              {
                "text": "Evidencia Estrógenos\\NVaginales:",
                "children": [
                  {
                    "text": "→ Revisión\\NCochrane (29):",
                    "children": [
                      {
                        "text": "• vs placebo: ↑ mejoría significativa",
                        "children": []
                      },
                      {
                        "text": "• Mejora:",
                        "children": [
                          {
                            "text": "- Sequedad vaginal",
                            "children": []
                          },
                          {
                            "text": "- Salud urogenital",
                            "children": []
                          }
                        ]
                      }
                    ]
                  },
                  {
                    "text": "→ Estudio\\NLatinoamericano:",
                    "children": [
                      {
                        "text": "• Sequedad vaginal = causa principal disfunción sexual posmenopáusicas",
                        "children": []
                      },
                      {
                        "text": "→ Evidencia\\Nanti-ITU (30):",
                        "children": [
                          {
                            "text": "• ↓ frecuencia vs placebo",
                            "children": []
                          }
                        ]
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "text": "ENFERMEDAD\\NCARDIOVASCULAR EN\\NCLIMATERIO:",
        "children": [
          {
            "text": "Generalidades:",
            "children": [
              {
                "text": "→ Causa principal morbimortalidad posmenopáusica",
                "children": []
              },
              {
                "text": "→ TH: potencial\\Nmejora perfil CV:",
                "children": [
                  {
                    "text": "• Función vascular",
                    "children": []
                  },
                  {
                    "text": "• Perfil lipídico",
                    "children": []
                  },
                  {
                    "text": "• Metabolismo glucídico",
                    "children": []
                  },
                  {
                    "text": "• PA",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ Cardioprotección\\N(31):",
                "children": [
                  {
                    "text": "• Si inicio cercano menopausia",
                    "children": []
                  },
                  {
                    "text": "• Si mantiene largo plazo",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "Hipótesis\\NAteromas:",
            "children": [
              {
                "text": "→ Estrógenos:",
                "children": [
                  {
                    "text": "• Posible retraso formación temprana",
                    "children": []
                  },
                  {
                    "text": "• Sin efecto/↑ accidentes CV si ateromas preexistentes",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ \"Ventana de\\Noportunidad\":",
                "children": [
                  {
                    "text": "• Protección: uso temprano",
                    "children": []
                  },
                  {
                    "text": "• Daño: inicio tardío",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "Efectos según\\NEdad:",
            "children": [
              {
                "text": "→ <60a + menopausia\\Nreciente + sin ECV:",
                "children": [
                  {
                    "text": "• No daño precoz",
                    "children": []
                  },
                  {
                    "text": "• ↓ mortalidad cardiopatía coronaria (9)",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ >60a o >10a\\Nposmenopausia:",
                "children": [
                  {
                    "text": "• ↑ riesgo eventos coronarios",
                    "children": []
                  },
                  {
                    "text": "• Principalmente primeros 2a uso (9)",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ Riesgo AVC:",
                "children": [
                  {
                    "text": "• ↑ con edad",
                    "children": []
                  },
                  {
                    "text": "• TH > 60a: ↑ riesgo",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "• Estudios vía\\Nadministración:",
            "children": [
              {
                "text": "- Sin diferencias significativas (32)",
                "children": []
              }
            ]
          },
          {
            "text": "EVENTOS CV\\NY TH SEGÚN EDAD:",
            "children": [
              {
                "text": "TE sola:",
                "children": [
                  {
                    "text": "→ 50-59a (n=1.637):",
                    "children": [
                      {
                        "text": "• EC: RR 0.63 (0.36-1.09)",
                        "children": []
                      },
                      {
                        "text": "• AVE: RR 0.89 (0.47-1.69)",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "→ 60-69a (n=2.387):",
                    "children": [
                      {
                        "text": "• EC: RR 0.94 (0.71-1.24)",
                        "children": []
                      },
                      {
                        "text": "• AVE: RR 1.62 (1.15-2.27)",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "→ 70-79a (n=1.286):",
                    "children": [
                      {
                        "text": "• EC: RR 1.13 (0.82-1.54)",
                        "children": []
                      },
                      {
                        "text": "• AVE: RR 1.21 (0.84-1.75)",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "TE+P:",
                "children": [
                  {
                    "text": "→ 50-59a (n=2.839):",
                    "children": [
                      {
                        "text": "• EC: RR 1.29 (0.79-2.12)",
                        "children": []
                      },
                      {
                        "text": "• AVE: RR 1.41 (0.75-2.65)",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "→ 60-69a (n=3.853):",
                    "children": [
                      {
                        "text": "• EC: RR 1.03 (0.74-1.43)",
                        "children": []
                      },
                      {
                        "text": "• AVE: RR 1.37 (0.95-1.97)",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "→ 70-79a (n=1.814):",
                    "children": [
                      {
                        "text": "• EC: RR 1.48 (1.04-2.11)",
                        "children": []
                      },
                      {
                        "text": "• AVE: RR 1.21 (0.82-1.78)",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "text": "Riesgo\\NTromboembolismo:",
            "children": [
              {
                "text": "→ TH oral:",
                "children": [
                  {
                    "text": "• Metaanálisis: ↑ riesgo primer ETE",
                    "children": [
                      {
                        "text": "- OR 2.5 (IC95%: 1.9-3. 4)",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "• Mayor riesgo:",
                    "children": [
                      {
                        "text": "- Primer año: OR 4.0 (IC95%: 2.9-5.7)",
                        "children": []
                      },
                      {
                        "text": "- >1a: OR 2.1 (IC95%: 1.3-3.8)",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "→ FR asociados (33):",
                "children": [
                  {
                    "text": "• Edad",
                    "children": []
                  },
                  {
                    "text": "• Obesidad",
                    "children": []
                  },
                  {
                    "text": "• Trombofilia",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ Prevención:",
                "children": [
                  {
                    "text": "• Vía transdérmica: evita efecto primer paso hepático = ↓ riesgo TEP (33)",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "text": "TH Y RIESGO CV:",
        "children": [
          {
            "text": "Aspectos Generales:",
            "children": [
              {
                "text": "→ No iniciar TH solo para prevención CV",
                "children": []
              },
              {
                "text": "→ Ventana oportunidad:",
                "children": [
                  {
                    "text": "• Primeros 10a post-menopausia",
                    "children": []
                  },
                  {
                    "text": "• Requiere selección adecuada riesgo-beneficio",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "Puntos Clave:",
            "children": [
              {
                "text": "→ EC:",
                "children": [
                  {
                    "text": "• ↑ riesgo:",
                    "children": [
                      {
                        "text": "- Edad >70a",
                        "children": []
                      },
                      {
                        "text": "- >20a post-menopausia",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "→ AVE:",
                "children": [
                  {
                    "text": "• Evaluar FR en toda\\Nposmenopáusica:",
                    "children": [
                      {
                        "text": "- Obesidad",
                        "children": []
                      },
                      {
                        "text": "- HTA",
                        "children": []
                      },
                      {
                        "text": "- Tabaquismo",
                        "children": []
                      },
                      {
                        "text": "- Historia previa",
                        "children": []
                      },
                      {
                        "text": "- AF",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "• TH oral dosis estándar >60a: ↑ significativo riesgo",
                    "children": []
                  },
                  {
                    "text": "• TH oral dosis baja: no ↑ riesgo",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ ETE:",
                "children": [
                  {
                    "text": "• = efecto adverso principal",
                    "children": []
                  },
                  {
                    "text": "• ↑ riesgo:",
                    "children": [
                      {
                        "text": "- Edad",
                        "children": []
                      },
                      {
                        "text": "- IMC",
                        "children": []
                      },
                      {
                        "text": "- Primeros años uso",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "text": "TH Y CA MAMA:",
        "children": [
          {
            "text": "Puntos Clave:",
            "children": [
              {
                "text": "→ Contraindicada si antecedente Ca mama",
                "children": []
              },
              {
                "text": "→ Factores riesgo:",
                "children": [
                  {
                    "text": "• Duración exposición E+P",
                    "children": []
                  },
                  {
                    "text": "• Dosis TH",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "Estudio WHI:",
            "children": [
              {
                "text": "→ Rama TE+P:",
                "children": [
                  {
                    "text": "• ↑ riesgo Ca mama 5° año",
                    "children": []
                  },
                  {
                    "text": "• RR 1.26 (IC95%: 1-1.59) (34)",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ Rama TE:",
                "children": [
                  {
                    "text": "• 7.1a seguimiento",
                    "children": []
                  },
                  {
                    "text": "• No ↑ riesgo",
                    "children": []
                  },
                  {
                    "text": "• RR 0.77 (IC95%: 0.59-1.01) (35)",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "Progestinas y\\NRiesgo Ca Mama:",
            "children": [
              {
                "text": "→ Naturales/similares progesterona:",
                "children": [
                  {
                    "text": "• Menor riesgo",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ Estudio cohorte\\Nfrancés (36):",
                "children": [
                  {
                    "text": "• 12a seguimiento",
                    "children": []
                  },
                  {
                    "text": "• n=80.000",
                    "children": []
                  },
                  {
                    "text": "• No ↑ riesgo:",
                    "children": []
                  }
                ]
              },
              {
                "text": "- Progesterona micronizada",
                "children": []
              },
              {
                "text": "- Didrogesterona",
                "children": [
                  {
                    "text": "• Sí ↑ riesgo:",
                    "children": [
                      {
                        "text": "- Clormadinona",
                        "children": []
                      },
                      {
                        "text": "- Nomegestrol",
                        "children": []
                      },
                      {
                        "text": "- Medroxi-progesterona",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "→ Necesarios más estudios",
                "children": []
              }
            ]
          },
          {
            "text": "Conclusión:",
            "children": [
              {
                "text": "→ Posible TH en muy sintomáticas + ↑ riesgo Ca mama",
                "children": []
              },
              {
                "text": "→ Requiere: información + vigilancia adecuadas",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "TH, MEMORIA Y\\NCOGNICIÓN:",
        "children": [
          {
            "text": "Efectos TH:",
            "children": [
              {
                "text": "→ Edad media:",
                "children": [
                  {
                    "text": "• Escaso efecto cognición",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ Post-menopausia quirúrgica:",
                "children": [
                  {
                    "text": "• Mejora memoria transitoria",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ >65a:",
                "children": [
                  {
                    "text": "• No mejora función cognitiva",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "Enfermedad\\NAlzheimer:",
            "children": [
              {
                "text": "→ Evidencia limitada",
                "children": []
              },
              {
                "text": "→ No mejora síntomas",
                "children": []
              },
              {
                "text": "→ WHIMS (37-40):",
                "children": [
                  {
                    "text": "• ↑ riesgo demencia mujeres mayores + estrógenos",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ Estudios observacionales:",
                "children": [
                  {
                    "text": "• ↓ riesgo Alzheimer si TH temprana (16)",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "Deterioro\\NCognitivo:",
            "children": [
              {
                "text": "→ No evidencia prevención",
                "children": []
              },
              {
                "text": "→ IOP:",
                "children": [
                  {
                    "text": "• Posible beneficio",
                    "children": []
                  },
                  {
                    "text": "• Ventana oportunidad (2, 41)",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "text": "TH Y SALUD ÓSEA:",
        "children": [
          {
            "text": "Efectos:",
            "children": [
              {
                "text": "→ ↓ resorción ósea posmenopáusica",
                "children": []
              },
              {
                "text": "→ ↓ fracturas\\Nosteoporóticas:",
                "children": [
                  {
                    "text": "• Vertebrales",
                    "children": []
                  },
                  {
                    "text": "• No vertebrales",
                    "children": []
                  },
                  {
                    "text": "• Incluso bajo riesgo",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "Indicaciones:",
            "children": [
              {
                "text": "→ No usar solo para prevención fracturas/tto osteoporosis",
                "children": []
              },
              {
                "text": "→ Excepciones:",
                "children": [
                  {
                    "text": "• IOP",
                    "children": []
                  },
                  {
                    "text": "• Menopausia precoz",
                    "children": []
                  },
                  {
                    "text": "• Casos excepcionales (2)",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "text": "SUSPENSIÓN TH:",
        "children": [
          {
            "text": "Decisión\\NIndividualizada:",
            "children": [
              {
                "text": "→ Evaluar:",
                "children": [
                  {
                    "text": "• Persistencia síntomas",
                    "children": []
                  },
                  {
                    "text": "• Severidad síntomas",
                    "children": []
                  },
                  {
                    "text": "• Riesgo/beneficio",
                    "children": []
                  },
                  {
                    "text": "• Mortalidad",
                    "children": []
                  },
                  {
                    "text": "• Riesgos acumulativos",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ Decisión conjunta\\Nmédico-paciente",
                "children": []
              }
            ]
          },
          {
            "text": "Forma de Suspensión:",
            "children": [
              {
                "text": "→ Escasa evidencia método óptimo",
                "children": []
              },
              {
                "text": "→ Opciones:",
                "children": [
                  {
                    "text": "• Abrupta",
                    "children": []
                  },
                  {
                    "text": "• Gradual",
                    "children": []
                  }
                ]
              },
              {
                "text": "→ Experiencia\\Nno publicada:",
                "children": [
                  {
                    "text": "• ↓ dosis periodos largos",
                    "children": []
                  },
                  {
                    "text": "• Varios meses-1a entre descensos",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "Evidencia:",
            "children": [
              {
                "text": "→ Estudio sueco (42):",
                "children": [
                  {
                    "text": "• n=81",
                    "children": []
                  },
                  {
                    "text": "• 6m seguimiento",
                    "children": []
                  },
                  {
                    "text": "• No diferencias según\\Nmodo suspensión:",
                    "children": [
                      {
                        "text": "- N° bochornos",
                        "children": []
                      },
                      {
                        "text": "- Calidad vida",
                        "children": []
                      },
                      {
                        "text": "- Necesidad reinicio TH",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "→ Estudios retiro\\Nprogresivo (43):",
                "children": [
                  {
                    "text": "• Periodos cortos",
                    "children": []
                  },
                  {
                    "text": "• Ejemplo: ½ dosis x 4\\Nsemanas pre-suspensión",
                    "children": []
                  },
                  {
                    "text": "• 50% probabilidad\\Nrecurrencia sx",
                    "children": []
                  },
                  {
                    "text": "• Independiente:",
                    "children": [
                      {
                        "text": "- Edad",
                        "children": []
                      },
                      {
                        "text": "- Duración TH",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "text": "Control anual, en invierno. ",
            "children": [
              {
                "text": "Disminuir dosis en invierno por\\Nmejor manojo de bochornos",
                "children": []
              }
            ]
          }
        ]
      }
    ]
  },
  "related_maps": [
    {
      "id": "map_1688",
      "title": "CLARITY-AD (2022)\\NLecanemab in Early Alzheimers Disease\\N\\nLecanemab reduce deterioro cognitivo 27%\\nen EA temprana con amiloide confirmado\\nPrimer anti-amiloide con beneficio clinico claro"
    },
    {
      "id": "map_1689",
      "title": "SPRINTT (2021)\\NSarcopenia and Physical\\NFragility in Older People:\\NMulti-component Treatment\\N\\n⭐ Ejercicio + nutrición reduce\\ndiscapacidad en fragilidad física\\ncon sarcopenia"
    },
    {
      "id": "map_1805",
      "title": "Deterioro Cognitivo Vascular (DCV)\\Ny Demencia Vascular"
    },
    {
      "id": "map_1107",
      "title": "Deterioro Cognitivo Vascular (DCV) y Demencia Vascular"
    },
    {
      "id": "map_1054",
      "title": "Evaluación de la Demencia y el Deterioro Cognitivo  UTD 2025"
    }
  ],
  "source_file": "Arteaga | CLIMATERIO Y TERAPIA HORMONAL-2024.smmx",
  "created": "2026-02-07T15:43:01.391595"
}